This search looks for keywords in all of the website’s content. Search tips
Filter by
- Agenda(1912)
- Annex to CHMP highlights(367)
- Annual Report(91)
- Application withdrawal assessment report(276)
- Committee meeting report(882)
- COVID-19 vaccine safety update(71)
- EPAR - All authorised presentations(1978)
- EPAR - Amended Product Information(1)
- EPAR - Assessment report - Variation(2706)
- EPAR - Assessment report on maintenance of orphan designation - Initial authorisation(140)
- EPAR - Assessment report on maintenance of orphan designation - Post-authorisation(42)
- EPAR - Conditions imposed on member states for safe and effective use(112)
- EPAR - Full risk management plan(0)
- EPAR - Overview(1974)
- EPAR - Paediatric investigation plan compliance statement(88)
- EPAR - Procedural steps taken and scientific information after authorisation(1885)
- EPAR - Procedural steps taken before authorisation(484)
- EPAR - Product Information(1974)
- EPAR - Public assessment report(1549)
- EPAR - Risk-management-plan summary(1139)
- EPAR - Scientific conclusion(1356)
- EPAR - Scientific Discussion(504)
- EPAR - Scientific Discussion - Variation(188)
- EPAR - Steps taken after authorisation when a cutoff date has been used(170)
- Herbal - Call for data(293)
- Herbal - Herbal monograph(118)
- Herbal - HMPC assessment report(476)
- Herbal - HMPC opinion on a European Union herbal monograph(247)
- Herbal - List of references supporting the assessment report(462)
- Herbal - Overview of comments received during consultation(164)
- Herbal - Summary of assessment report for the public(120)
- Herbal – European Union herbal monograph(330)
- Herbal – European Union list entry(19)
- Leaflet(71)
- Maximum Residue Limits - Divergent opinion(2)
- Maximum Residue Limits - Opinion(88)
- Maximum Residue Limits - Report(803)
- Maximum Residue Limits - Summary of opinion(14)
- Medicine QA(456)
- Medicines under additional monitoring(22)
- Minutes(1249)
- Newsletter(299)
- Opinion outside EU - All presentations(14)
- Opinion outside EU - Assessment report - Variation(9)
- Opinion outside EU - Medicine questions and answers(1)
- Opinion outside EU - Procedural steps taken and scientific information after opinion(11)
- Opinion outside EU - Procedural steps taken before opinion(3)
- Opinion outside EU - Product information(15)
- Opinion outside EU - Public assessment report(12)
- Opinion outside EU - Risk-management-plan summary(11)
- Opinion outside EU - Scientific discussion(4)
- Opinion outside EU - Summary for the public(15)
- Opinion outside EU - Summary of opinion(3)
- Opinion outside EU - Summary of opinion - Initial authorisation(9)
- Opinion outside EU - Withdrawal assessment report(1)
- Orphan designation(2420)
- Orphan review(106)
- Other(4057)
- Overview of comments(330)
- Parallel distribution(1)
- Periodic safety update single assessment(2760)
- PIP - Notification of discontinuation of a paediatric development which is covered by an agreed PIP decision(109)
- PIP - Paediatric-investigation-plan summary(93)
- PIP decision(5478)
- Position statement(29)
- PRAC recommendation on signal(164)
- Presentation(5305)
- Press Release(1708)
- Procurement(73)
- Public Statement(485)
- Recommendation on medication errors(26)
- Recruitment(38)
- Referrals document(2773)
- Regulatory and procedural guideline(723)
- Report(1619)
- Scientific guideline(2464)
- Standard Operating Procedure - SOP(129)
- Summary of opinion(1223)
- Summary of opinion - Initial authorisation(1672)
- Supply shortage(58)
- Template or form(479)
- Withdrawal letter(290)
- Work Instruction - WIN(61)
- Work programme(151)
- (-)Direct healthcare professional communication(122)
- Advanced therapies(0)
- Antimicrobial resistance(0)
- Biologicals(0)
- Biosimilars(0)
- Brexit(0)
- Careers(0)
- Clinical trials(0)
- Compassionate use(0)
- Compliance and inspections(0)
- Corporate(0)
- COVID-19(5)
- Data on medicines(0)
- Early access(0)
- Fees(0)
- Generic and hybrid medicines(2)
- Governance(0)
- Innovation(0)
- Maximum residue limit(0)
- Medication error(0)
- Medicines(46)
- Medicines for use outside the EU(0)
- Medicine shortages(22)
- Mpox(0)
- Paediatrics(0)
- Parallel distribution(0)
- Pharmacovigilance(56)
- Procurement(0)
- Product information(10)
- Quality of medicines(7)
- Rare diseases(0)
- Referrals(11)
- Regulatory and procedural guidance(0)
- Research and development(0)
- Scientific advice(0)
- Scientific guidelines(0)
- SME(0)
- Vaccines(4)
- Veterinary limited markets(0)
Search results (122)
Direct healthcare professional communication (DHPC) : Giapreza (angiotensin II) 2.5mg/ml concentrate for solution for infusion: potentially low fill vials and important information regarding instructions for use
English (EN) (108.66 KB - PDF)
Direct healthcare professional communication (DHPC) : Paxlovid (nirmatrelvir; ritonavir): reminder of life-threatening and fatal drug-drug interactions with certain immunosuppressants, including tacrolimus
English (EN) (118.05 KB - PDF)
Direct healthcare professional communication (DHPC) : Valproate-containing medicines - new measures regarding the potential risk of neurodevelopmental disorders in children of fathers treated with valproate in the 3 months prior to conception
English (EN) (253.94 KB - PDF)
Direct healthcare professional communication (DHPC) : Pseudoephedrine – Risks of posterior reversible encephalopathy syndrome (PRES) and reversible cerebral vasoconstriction syndrome (RCVS)
English (EN) (114.2 KB - PDF)
Direct healthcare professional communication (DHPC) : Voxzogo (vosoritide): change to administration syringe and needle leading to product administration in Units (U) instead of mL
English (EN) (164.15 KB - PDF)
Direct healthcare professional communication (DHPC) : Leqvio (inclisiran) 284 mg solution for injection in pre-filled syringe: Important information regarding instructions for use before injection
English (EN) (201.75 KB - PDF)
Direct healthcare professional communication (DHPC): Omega-3-acid ethyl ester medicines: dose-dependent increased risk of atrial fibrillation in patients with established cardiovascular diseases or cardiovascular risk factors
English (EN) (221.76 KB - PDF)
Direct healthcare professional communication (DHPC): Integrilin (eptifibatide): Discontinuation of manufacturing of Integrilin
English (EN) (141.91 KB - PDF)
Topiramate and topiramate/phentermine combination: New restrictions to prevent exposure during pregnancy
English (EN) (210.68 KB - PDF)
Direct healthcare professional communication (DHPC): Vaxneuvance (pneumococcal polysaccharide conjugate vaccine) suspension for injection: Important information regarding the potential for breakage of Vaxneuvance pre-filled syringes
English (EN) (824.22 KB - PDF)